Cargando…
Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report
BACKGROUND: Paclitaxel plus bevacizumab have shown a high response rate and prolonged progression-free survival in metastatic breast cancer patients. However, overall survival was not prolonged. Thus, no conclusion has been made on the effectiveness of bevacizumab. In our report, taxane plus bevaciz...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707777/ https://www.ncbi.nlm.nih.gov/pubmed/23830415 http://dx.doi.org/10.1186/1756-0500-6-254 |
_version_ | 1782276533556084736 |
---|---|
author | Ishizuna, Kazuo Ninomiya, Jun Kojima, Makoto Kawashima, Miho Nozaki, Miwako Yamagishi, Hidetsugu Ueda, Yoshihiko Oya, Masatoshi |
author_facet | Ishizuna, Kazuo Ninomiya, Jun Kojima, Makoto Kawashima, Miho Nozaki, Miwako Yamagishi, Hidetsugu Ueda, Yoshihiko Oya, Masatoshi |
author_sort | Ishizuna, Kazuo |
collection | PubMed |
description | BACKGROUND: Paclitaxel plus bevacizumab have shown a high response rate and prolonged progression-free survival in metastatic breast cancer patients. However, overall survival was not prolonged. Thus, no conclusion has been made on the effectiveness of bevacizumab. In our report, taxane plus bevacizumab were used to treat a metastatic breast cancer patient with taxane resistance, and a good therapeutic result was obtained. CASE PRESENTATION: The patient was a 68-year-old woman with a non-contributory history. In September 2004, she underwent a pectoral muscle-conserving mastectomy with axillary dissection for right-sided breast cancer (pT3N0M0-stage IIB, estrogen receptor positive, progesterone receptor negative, and human epidermal growth factor receptor type 2 negative). Adjuvant therapy consisted of 6 cycles of cyclophosphamide, epirubicin and fluorouracil, and subsequent oral anastrozole. In August 2007, the patient developed a recurrence in the left axillary lymph node. The chemotherapy was changed to high-dose toremifene, and radiation therapy was also performed. The patient achieved a complete response. In April 2009, CT showed left axillary lymph node enlargement once again and multiple lung metastases. Hormone therapy was changed to exemestane and long-term stable disease was achieved. In March 2011, the lung and left axillary lymph node metastases were enlarged and progressive disease was noted. Thus, the tumors were determined to be resistant to hormone therapy, and weekly paclitaxel was begun in May. Since partial response was achieved, this therapy was continued. In December, CT showed that lung and axillary lymph node metastases were enlarged and progressive disease was observed. Therefore, the tumors were determined to be resistant to paclitaxel. In January 2012, bevacizumab and weekly paclitaxel were begun. In April, lung and axillary lymph node metastases were reduced in size, and partial response was achieved. Thereafter the same treatment has been continued, and the patient has been followed up without clinical exacerbation as of January 2013. CONCLUSION: Taxane plus bevacizumab were used to treat a metastatic breast cancer patient with taxane resistance, and a good therapeutic result was obtained. This result is considered important in increasing treatment options for patients with taxane resistance or patients using adjuvant taxane-based therapy and in examining the effectiveness of bevacizumab in metastatic breast cancer patients. |
format | Online Article Text |
id | pubmed-3707777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37077772013-07-11 Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report Ishizuna, Kazuo Ninomiya, Jun Kojima, Makoto Kawashima, Miho Nozaki, Miwako Yamagishi, Hidetsugu Ueda, Yoshihiko Oya, Masatoshi BMC Res Notes Case Report BACKGROUND: Paclitaxel plus bevacizumab have shown a high response rate and prolonged progression-free survival in metastatic breast cancer patients. However, overall survival was not prolonged. Thus, no conclusion has been made on the effectiveness of bevacizumab. In our report, taxane plus bevacizumab were used to treat a metastatic breast cancer patient with taxane resistance, and a good therapeutic result was obtained. CASE PRESENTATION: The patient was a 68-year-old woman with a non-contributory history. In September 2004, she underwent a pectoral muscle-conserving mastectomy with axillary dissection for right-sided breast cancer (pT3N0M0-stage IIB, estrogen receptor positive, progesterone receptor negative, and human epidermal growth factor receptor type 2 negative). Adjuvant therapy consisted of 6 cycles of cyclophosphamide, epirubicin and fluorouracil, and subsequent oral anastrozole. In August 2007, the patient developed a recurrence in the left axillary lymph node. The chemotherapy was changed to high-dose toremifene, and radiation therapy was also performed. The patient achieved a complete response. In April 2009, CT showed left axillary lymph node enlargement once again and multiple lung metastases. Hormone therapy was changed to exemestane and long-term stable disease was achieved. In March 2011, the lung and left axillary lymph node metastases were enlarged and progressive disease was noted. Thus, the tumors were determined to be resistant to hormone therapy, and weekly paclitaxel was begun in May. Since partial response was achieved, this therapy was continued. In December, CT showed that lung and axillary lymph node metastases were enlarged and progressive disease was observed. Therefore, the tumors were determined to be resistant to paclitaxel. In January 2012, bevacizumab and weekly paclitaxel were begun. In April, lung and axillary lymph node metastases were reduced in size, and partial response was achieved. Thereafter the same treatment has been continued, and the patient has been followed up without clinical exacerbation as of January 2013. CONCLUSION: Taxane plus bevacizumab were used to treat a metastatic breast cancer patient with taxane resistance, and a good therapeutic result was obtained. This result is considered important in increasing treatment options for patients with taxane resistance or patients using adjuvant taxane-based therapy and in examining the effectiveness of bevacizumab in metastatic breast cancer patients. BioMed Central 2013-07-06 /pmc/articles/PMC3707777/ /pubmed/23830415 http://dx.doi.org/10.1186/1756-0500-6-254 Text en Copyright © 2013 Ishizuna et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Ishizuna, Kazuo Ninomiya, Jun Kojima, Makoto Kawashima, Miho Nozaki, Miwako Yamagishi, Hidetsugu Ueda, Yoshihiko Oya, Masatoshi Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
title | Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
title_full | Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
title_fullStr | Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
title_full_unstemmed | Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
title_short | Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
title_sort | paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707777/ https://www.ncbi.nlm.nih.gov/pubmed/23830415 http://dx.doi.org/10.1186/1756-0500-6-254 |
work_keys_str_mv | AT ishizunakazuo paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT ninomiyajun paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT kojimamakoto paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT kawashimamiho paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT nozakimiwako paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT yamagishihidetsugu paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT uedayoshihiko paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport AT oyamasatoshi paclitaxelresistantadvancedrecurrentbreastcanceracaseofpartialresponseduetoadditionofbevacizumabtopaclitaxeltherapyacasereport |